Association of total peripheral inflammation with lower frontal and temporal lobe volumes in early-stage bipolar disorder: A proof-of-concept study

David J. Bond, Ana C. Andreazza, Ivan J. Torres, William G. Honer, Raymond W. Lam, Lakshmi N. Yatham

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Background: We previously reported that in early-stage bipolar disorder (BD), frontal and temporal lobe volume reductions were more pronounced in patients with elevated BMI and more rapidly progressive in patients with additional weight gain. Elevated BMI is a pro-inflammatory state, and inflammation may contribute to brain volume reductions in BD. However, few studies have investigated the relationship between inflammation and brain volumes. Methods: We conducted a proof-of-concept analysis to investigate whether a composite measure of total peripheral inflammation derived from 9 cytokines predicted lower frontal and temporal lobe volumes, measured with 3 T MRI, in early-stage BD. Results: In 25 early-stage patients, linear regression models showed that greater total inflammation predicted lower white matter (WM) volumes in the left frontal lobe (β = −0.691, p = 0.001) and bilateral temporal lobes (left: β = −0.617, p = 0.003; right: β = −0.636, p = 0.001). Greater inflammation also predicted lower right frontal WM, although this did not survive correction for multiple comparisons (β = −0.557, p = 0.020). It did not predict frontal or temporal GM. Total inflammation was a stronger predictor of lower WM volumes than were individual cytokines. Limitations: Although the magnitude of the association between total inflammation and lower WM volumes was large, our sample was small. Our findings require confirmation in further studies, with samples large enough to determine whether inflammation mediates the relationship between elevated BMI and brain volumes. Conclusions: This study supports the hypothesis that inflammation contributes to brain volume reductions in BD and suggests that total inflammatory burden best captures the impact of inflammation on the brain.

Original languageEnglish (US)
Pages (from-to)229-234
Number of pages6
JournalJournal of Affective Disorders
Volume319
DOIs
StatePublished - Dec 15 2022

Bibliographical note

Funding Information:
Dr. Bond has sat on advisory boards and/or has received research funding from Alkermes, Myriad Genetics, the National Institutes of Health, NuBiyota, Pfizer, the University of Minnesota Department of Psychiatry and Behavioral Sciences, and the University of Minnesota Foundation.

Funding Information:
The Systematic Treatment Optimization Program for Early Mania (STOP-EM) was supported by an unrestricted grant to LNY from AstraZeneca Canada . The analysis of serum biomarkers was supported by an investigator-initiated grant to DJB from Pfizer Canada ( WS1952848 ). The sponsors had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Funding Information:
Dr. Andreazza has received research funding from the Brain and Behaviour Foundation (formerly NARSAD), CIHR, Canada Research Chair, and philanthropy. She is the scientific director of the Mitochondrial Innovation Initiative, a strategic initiative of the University of Toronto.

Funding Information:
Dr. Torres has been a consultant and/or has received speaker fees and/or receives research funding from CIHR, Lundbeck Canada, and Sumitomo Dainippon.

Funding Information:
Dr. Lam has been a consultant and/or has received speaker fees and/or has sat on advisory boards and/or has received research funding from Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, Unity Health, Vancouver Coastal Health Research Institute, and VGH-UBCH Foundation.

Funding Information:
Dr. Yatham has been a consultant and/or has received speaker fees and/or has sat on advisory boards and/or has received research funding from Abbvie, Alkermes, Allergan, Canadian Network for Mood and Anxiety Treatments (CANMAT), Canadian Institutes of Health Research (CIHR), Dainippon Sumitomo Pharma, Gedeon Richter, Intracellular Therapies, Lundbeck, Merck, Otsuka, Sanofi and Sunovion.

Publisher Copyright:
© 2022

Keywords

  • Bipolar disorder
  • Cytokines
  • Inflammation
  • Magnetic resonance imaging
  • White matter

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint

Dive into the research topics of 'Association of total peripheral inflammation with lower frontal and temporal lobe volumes in early-stage bipolar disorder: A proof-of-concept study'. Together they form a unique fingerprint.

Cite this